Skip to main content

Ryan Arthur F's Form 4 filing

Regeneron Pharmaceuticals, Inc. (REGN) · filed Dec 2, 2021

Accession no.
0001883850-21-000016
Filed
Dec 2, 2021
Trade date
Nov 16-Dec 1, 2021
Filing delay
16 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 12 non-derivative transactions. Open-market sales total $63.8K. It was filed 16 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ryan Arthur FCIK 0001187443Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 16, 2021Common StockGGiftDisposed−500$0.00$022,591Direct
Dec 1, 2021Common StockSSaleDisposed−1$631.15−$631.1522,590Direct
Dec 1, 2021Common StockSSaleDisposed−7$632.63F2−$4,428.4122,583Direct
Dec 1, 2021Common StockSSaleDisposed−2$633.47F3−$1,266.9422,581Direct
Dec 1, 2021Common StockSSaleDisposed−11$634.56F4−$6,980.1622,570Direct
Dec 1, 2021Common StockSSaleDisposed−9$635.36F5−$5,718.2422,561Direct
Dec 1, 2021Common StockSSaleDisposed−1$636.50−$636.522,560Direct
Dec 1, 2021Common StockSSaleDisposed−22$637.75F6−$14,030.522,538Direct
Dec 1, 2021Common StockSSaleDisposed−12$638.62F7−$7,663.4422,526Direct
Dec 1, 2021Common StockSSaleDisposed−24$639.49F8−$15,347.7622,502Direct
Dec 1, 2021Common StockSSaleDisposed−5$640.47F9−$3,202.3522,497Direct
Dec 1, 2021Common StockSSaleDisposed−6$641.23F10−$3,847.3822,491Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents volume-weighted average price of sales of 7 shares of Company stock on December 1, 2021 at prices ranging from $632.00 to $632.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents volume-weighted average price of sales of 2 shares of Company stock on December 1, 2021 at prices ranging from $633.21 to $633.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

Represents volume-weighted average price of sales of 11 shares of Company stock on December 1, 2021 at prices ranging from $634.05 to $634.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F5

Represents volume-weighted average price of sales of 9 shares of Company stock on December 1, 2021 at prices ranging from $635.06 to $635.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F6

Represents volume-weighted average price of sales of 22 shares of Company stock on December 1, 2021 at prices ranging from $637.17 to $637.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F7

Represents volume-weighted average price of sales of 12 shares of Company stock on December 1, 2021 at prices ranging from $638.03 to $638.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F8

Represents volume-weighted average price of sales of 24 shares of Company stock on December 1, 2021 at prices ranging from $639.01 to $639.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F9

Represents volume-weighted average price of sales of 5 shares of Company stock on December 1, 2021 at prices ranging from $640.01 to $640.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F10

Represents volume-weighted average price of sales of 6 shares of Company stock on December 1, 2021 at prices ranging from $641.01 to $641.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)